HomeAKTX • NASDAQ
Akari Therapeutics PLC
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 3.53M | -41.14% |
Net income | -3.71M | 33.44% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -3.52M | 41.07% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.58M | 97.10% |
Total assets | 50.96M | 1,738.35% |
Total liabilities | 29.21M | 361.87% |
Total equity | 21.75M | — |
Shares outstanding | 27.29M | — |
Price to book | 1.61 | — |
Return on assets | -17.36% | — |
Return on capital | -35.91% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -3.71M | 33.44% |
Cash from operations | -2.15M | 46.83% |
Cash from investing | — | — |
Cash from financing | 2.13M | 40.89% |
Net change in cash | -17.00K | 99.33% |
Free cash flow | -240.50K | — |
Previous close
$1.29
Day range
$1.21 - $1.37
Year range
$0.85 - $4.40
Market cap
42.96M USD
Avg Volume
24.08K
Primary exchange
NASDAQ
About
Founded
2004
Headquarters
Website
Employees
8
